Couple-level dyslipidemia and embryological and cumulative pregnancy outcomes in IVF/ICSI cycles: a single-center retrospective cohort study - Summary - MDSpire

Couple-level dyslipidemia and embryological and cumulative pregnancy outcomes in IVF/ICSI cycles: a single-center retrospective cohort study

  • By

  • Ruobing Lei

  • Shuyi Chen

  • Weihong Li

  • June 18, 2026

  • 0 min

Share

Objective:

To investigate associations of dyslipidemia in both partners with embryological and cumulative pregnancy outcomes in couples undergoing IVF/ICSI.

Approach:
    Key Findings:
    • Women with dyslipidemia had longer stimulation duration and higher total gonadotropin dose.
    • Male dyslipidemia was associated with fewer transferable embryos and lower fertilization rates.
    • Bilateral dyslipidemia correlated with less favorable embryological outcomes.
    • Female dyslipidemia increased odds of cumulative miscarriage (aOR = 4.455) and decreased odds of cumulative live birth (aOR = 0.335).
    • Male dyslipidemia decreased odds of cumulative live birth (aOR = 0.309).
    • Bilateral dyslipidemia was linked to higher odds of cumulative miscarriage (aOR = 10.579) and lower odds of cumulative live birth (aOR = 0.116).
    Interpretation:

    Dyslipidemia in either or both partners was associated with less favorable embryological and cumulative pregnancy outcomes in IVF/ICSI cycles.

    Limitations:
    • Retrospective design may limit causal inferences.
    • Limited event numbers may affect the robustness of findings.
    Conclusion:

    Couples with bilateral dyslipidemia showed less favorable outcome patterns.

Original Source(s)

Couple-level dyslipidemia and embryological and cumulative pregnancy outcomes in IVF/ICSI cycles: a single-center retrospective cohort study

  • by Ruobing Lei, Shuyi Chen, Weihong Li

  • June 18, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis